MedTrace Logo

Comparison of MCO HD on Markers of Vascular Health Compared With On-Line Haemodiafiltration

NCT03510520 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2019-08-09

No results posted yet for this study

Summary

The aim of this study is to evaluate haemodialysis treatment using a medium cut-off dialysis membrane (Theranova) compared with on-line haemodiafiltration treatment with respect to markers of endothelial health (plasma endothelial microvesicle levels, pro-inflammatory and pro-coagulant markers).

This study will also compare the 2 treatment modalities with respect to several other outcome measures including patient-reported outcome measures, haemodynamic parameters and advanced glycation end-products.

Conditions

Interventions

DEVICE

Medium Cut-Off Haemodialysis

Treatment with medium cut-off haemodialysis using the Theranova dialysis membrane 3 times per week for 6 months

DEVICE

On-Line Haemodiafiltration

Treatment with on-line haemodiafiltration (HDF) 3 times per week for 6 months (Conventional treatment)

Sponsors & Collaborators

  • Manchester Metropolitan University

    collaborator OTHER

  • Baxter Healthcare Corporation

    collaborator INDUSTRY

  • Manchester University NHS Foundation Trust

    lead OTHER_GOV

Principal Investigators

  • Sandip Mitra, MBBS · Manchester University NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-14
Primary Completion
2019-05-09
Completion
2019-05-09

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03510520 on ClinicalTrials.gov